Učitavanje...
Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer
Trastuzumab deruxtecan (T-DXd) is a novel anti-human epidermal growth factor receptor 2 (HER2) antibody–drug conjugate composed of a monoclonal anti-HER2 antibody and a topoisomerase I inhibitor, DX-8951 derivative (an exatecan derivative). T-DXd showed potential anti-tumor activities in HER2-positi...
Spremljeno u:
| Izdano u: | Ther Adv Med Oncol |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7797586/ https://ncbi.nlm.nih.gov/pubmed/33473250 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920986518 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|